Heron Therapeutics: SUSTOL ER injection net product sales approx. $10M in Q4
Heron Therapeutics highlighted progress in the company's pain management and CINV franchises. SUSTOL extended-release injection fourth-quarter 2017 net product sales were approximately $10M, up 16% from third-quarter 2017 net product sales of $8.6M. SUSTOL full-year 2017 net product sales were approximately $31M, versus guidance of $26M-$30M. Net product sales guidance for full-year 2018 for the CINV franchise is $60M-$70M. On January 1, 2018, a product-specific billing code, or permanent J-code, for SUSTOL became available. The new J-code was assigned by the Centers for Medicare and Medicaid Services and will help simplify the billing and reimbursement process for prescribers of SUSTOL. Heron completed enrollment in its two pivotal Phase 3 efficacy studies in bunionectomy and hernia repair. Heron anticipates reporting top-line results in the first half of 2018 and expects to file an NDA with the FDA in the second half of 2018.